Morgan Stanley’s Acer Therapeutics Inc ACER Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1
| Closed | -$1 | – | 8008 |
|
|
2023
Q3 | $1 | Sell |
1
-740
| -100% | -$608 | ﹤0.01% | 7606 |
|
|
2023
Q2 | $685 | Sell |
741
-1,581
| -68% | -$1.4K | ﹤0.01% | 7344 |
|
|
2023
Q1 | $1.76K | Buy |
2,322
+134
| +6% | +$264 | ﹤0.01% | 7264 |
|
|
2022
Q4 | $5.49K | Buy |
2,188
+14
| +0.6% | +$24 | ﹤0.01% | 7123 |
|
|
2022
Q3 | $3K | Sell |
2,174
-1
| -0% | -$1 | ﹤0.01% | 7421 |
|
|
2022
Q2 | $3K | Buy |
2,175
+2,167
| +27,088% | +$4.54K | ﹤0.01% | 7546 |
|
|
2022
Q1 | $0 | Buy |
8
+7
| +700% | +$17 | ﹤0.01% | 8222 |
|
|
2021
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 8198 |
|
|
2021
Q3 | $0 | Buy |
+1
| New | +$3 | ﹤0.01% | 8080 |
|
|
2020
Q3 | – | Sell |
-3,857
| Closed | -$13K | – | 6868 |
|
|
2020
Q2 | $13K | Buy |
3,857
+1,271
| +49% | +$3.59K | ﹤0.01% | 6108 |
|
|
2020
Q1 | $5K | Sell |
2,586
-4,151
| -62% | -$15.2K | ﹤0.01% | 6234 |
|
|
2019
Q4 | $27K | Buy |
6,737
+255
| +4% | +$867 | ﹤0.01% | 6033 |
|
|
2019
Q3 | $21K | Buy |
6,482
+3,499
| +117% | +$10.3K | ﹤0.01% | 6001 |
|
|
2019
Q2 | $12K | Sell |
2,983
-2,642
| -47% | -$50.4K | ﹤0.01% | 6088 |
|
|
2019
Q1 | $137K | Buy |
5,625
+2,996
| +114% | +$70.7K | ﹤0.01% | 5246 |
|
|
2018
Q4 | $53K | Sell |
2,629
-578
| -18% | -$13.3K | ﹤0.01% | 5749 |
|
|
2018
Q3 | $98K | Buy |
3,207
+3,191
| +19,944% | +$85.5K | ﹤0.01% | 5697 |
|
|
2018
Q2 | $0 | Buy |
16
+13
| +433% | +$247 | ﹤0.01% | 6784 |
|
|
2018
Q1 | $0 | Sell |
3
-2
| -40% | -$37 | ﹤0.01% | 6738 |
|
|
2017
Q4 | $0 | Sell |
5
-34
| -87% | -$554 | ﹤0.01% | 6695 |
|
|
2017
Q3 | $1K | Sell |
39
-116
| -75% | -$1.13K | ﹤0.01% | 6482 |
|
|
2017
Q2 | $1K | Hold |
155
| – | – | ﹤0.01% | 6538 |
|
|
2017
Q1 | $1K | Sell |
155
-3,497
| -96% | -$34.4K | ﹤0.01% | 6521 |
|
|
2016
Q4 | $35K | Buy |
3,652
+3,602
| +7,204% | +$63K | ﹤0.01% | 5846 |
|
|
2016
Q3 | $2K | Buy |
50
+3
| +6% | +$126 | ﹤0.01% | 6380 |
|
|
2016
Q2 | $2K | Sell |
47
-1
| -2% | -$30 | ﹤0.01% | 6377 |
|
|
2016
Q1 | $1K | Sell |
48
-38
| -44% | -$833 | ﹤0.01% | 6495 |
|
|
2015
Q4 | $2K | Buy |
86
+38
| +79% | +$1.26K | ﹤0.01% | 6518 |
|
|
2015
Q3 | $2K | Hold |
48
| – | – | ﹤0.01% | 6497 |
|
|
2015
Q2 | $2K | Hold |
48
| – | – | ﹤0.01% | 6522 |
|
|
2015
Q1 | $2K | Hold |
48
| – | – | ﹤0.01% | 6440 |
|
|
2014
Q4 | $3K | Hold |
48
| – | – | ﹤0.01% | 6406 |
|
|
2014
Q3 | $4K | Hold |
48
| – | – | ﹤0.01% | 6370 |
|
|
2014
Q2 | $7K | Sell |
48
-595
| -93% | -$78.8K | ﹤0.01% | 6253 |
|
|
2014
Q1 | $100K | Buy |
643
+596
| +1,268% | +$90.4K | ﹤0.01% | 5446 |
|
|
2013
Q4 | $7K | Buy |
+47
| New | +$7.65K | ﹤0.01% | 6111 |
|
Other funds holding ACER
Morgan Stanley's ACER Position: Q4 2023 in Review
Morgan Stanley sold out of Acer Therapeutics Inc (ACER) in Q4 2023, closing a stake of 1 share — an estimated $1 sold.
Morgan Stanley first reported a position in ACER in Q4 2013 and held it in 36 quarters. The position peaked at $137K in Q1 2019. 2 funds tracked by Wall St. Rank hold ACER as of Q4 2023.
- Morgan Stanley reported no remaining Acer Therapeutics Inc position as of Q4 2023 after selling out during the quarter.
- Morgan Stanley sold 1 Acer Therapeutics Inc share in Q4 2023, an estimated $1.
- Morgan Stanley first reported a position in Acer Therapeutics Inc in Q4 2013 and held it in 36 quarters.
- Morgan Stanley's Acer Therapeutics Inc position peaked at $137K in Q1 2019.
- 2 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q4 2023.
Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.